Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 5, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2015-01-29
DOI
10.3389/fonc.2015.00005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activation of Multiple ERBB Family Receptors Mediates Glioblastoma Cancer Stem-like Cell Resistance to EGFR-Targeted Inhibition
- (2015) Paul A. Clark et al. NEOPLASIA
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) R. Stupp et al. ANNALS OF ONCOLOGY
- Current management of advanced melanoma: a transformed landscape
- (2014) David E. Gyorki et al. ANZ JOURNAL OF SURGERY
- Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
- (2014) Wenhua Liang et al. PLoS One
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review
- (2014) XiongWen Yang et al. Current Oncology Reports
- Pazopanib for the treatment of advanced renal cell cancer
- (2014) Bernard Escudier et al. Expert Opinion on Orphan Drugs
- EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma
- (2013) Qi-Wen Fan et al. CANCER CELL
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- The role of GM-CSF in enhancing immunotherapy of cancer
- (2013) Steve H Thorne Immunotherapy
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
- (2013) Ian F Tannock et al. LANCET ONCOLOGY
- Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
- (2013) David A. Nathanson et al. SCIENCE
- Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro
- (2013) Liang-Hua Wang et al. TUMOR BIOLOGY
- MicroRNA in Human Glioma
- (2013) Mengfeng Li et al. Cancers
- Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
- (2012) Rachana Patel et al. CURRENT PHARMACEUTICAL DESIGN
- Nimotuzumab treatment of malignant gliomas
- (2012) Udo Bode et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas
- (2012) Gordon Li et al. JOURNAL OF NEURO-ONCOLOGY
- EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms
- (2012) C A Del Vecchio et al. ONCOGENE
- Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240
- (2012) T. R. Fenton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
- (2012) Igor Vivanco et al. Cancer Discovery
- Heterogeneity Maintenance in Glioblastoma: A Social Network
- (2011) R. Bonavia et al. CANCER RESEARCH
- Glioblastoma survival in the United States before and during the temozolomide era
- (2011) Derek R. Johnson et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
- (2011) Janessa J. Laskin et al. Journal of Thoracic Oncology
- Transferrin Antibodies Into the Brain
- (2011) Mark S Dennis et al. NEUROPSYCHOPHARMACOLOGY
- Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells
- (2011) J. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling
- (2011) Kyung Min Lee et al. RADIOTHERAPY AND ONCOLOGY
- Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance
- (2011) K. Tanaka et al. Cancer Discovery
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Escape from targeted inhibition: The dark side of kinase inhibitor therapy
- (2010) Jill Wykosky et al. CELL CYCLE
- Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies
- (2010) Aude-Helene Capietto et al. CURRENT DRUG TARGETS
- RNA interference therapy for glioblastoma
- (2010) Dongsheng Guo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence
- (2010) Anna Elisa Quatrale Frontiers in Bioscience-Landmark
- Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
- (2010) M.-d.-M. Inda et al. GENES & DEVELOPMENT
- A Phase II study of anti–epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme
- (2010) Linna Li et al. JOURNAL OF NEUROSURGERY
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
- (2009) B. Neyns et al. ANNALS OF ONCOLOGY
- Characteristics of compounds that cross the blood-brain barrier
- (2009) William A Banks BMC Neurology
- EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma
- (2009) Bryan D. Choi et al. BRAIN PATHOLOGY
- A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
- (2009) Brian Thiessen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The EGFRvIII variant in glioblastoma multiforme
- (2009) Hui K. Gan et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis
- (2009) Jeong-Eun Kim et al. LUNG CANCER
- Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
- (2009) G. Karpel-Massler et al. MOLECULAR CANCER RESEARCH
- An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
- (2009) J. H. Sampson et al. MOLECULAR CANCER THERAPEUTICS
- The promises and pitfalls of RNA-interference-based therapeutics
- (2009) Daniela Castanotto et al. NATURE
- microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma
- (2008) B. Kefas et al. CANCER RESEARCH
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
- (2008) John H. Sampson et al. SEMINARS IN IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started